[8-K] REVIVA PHARMACEUTICALS HOLDINGS, INC. Reports Material Event

Rhea-AI Filing Summary

Reviva Pharmaceuticals Holdings, Inc. (RVPH) furnished an 8-K announcing it issued a press release with financial information and operating metrics for the fiscal quarter ended September 30, 2025, and discussed its business outlook.

The materials were furnished under Items 2.02 and 7.01 and are not deemed “filed” for liability purposes. The press release is included as Exhibit 99.1.

false 0001742927 0001742927 2025-11-13 2025-11-13 0001742927 rvph:CommonStockParValue00001PerShareCustomMember 2025-11-13 2025-11-13 0001742927 rvph:WarrantsToPurchaseOneShareOfCommonStockCustomMember 2025-11-13 2025-11-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT 

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 

Date of Report (Date of earliest event reported): November 13, 2025

REVIVA PHARMACEUTICALS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-38634		85-4306526
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

10080 N Wolfe Road, Suite SW3-200, Cupertino, CA		95014
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (408) 501-8881

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act.

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		RVPH		Nasdaq Capital Market
Warrants to purchase one share of Common Stock		RVPHW		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

Reviva Pharmaceuticals Holdings, Inc. (the “Company”) issued a press release on November 13, 2025, disclosing financial information and operating metrics for its fiscal quarter ended September 30, 2025 and discussing its business outlook. A copy of the Company’s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

See “Item 2.02 Results of Operations and Financial Condition” above.

The information in this Current Report on Form 8-K under Items 2.02 and 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) The following exhibit is furnished with this report:

Exhibit No.		Description
99.1		Press Release issued by Reviva Pharmaceuticals Holdings, Inc., dated November 13, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	REVIVA PHARMACEUTICALS HOLDINGS, INC.
Date: November 13, 2025	By:	/s/ Narayan Prabhu
	Name: Title:	Narayan Prabhu Chief Financial Officer

FAQ

What did RVPH disclose in this 8-K?

The company furnished a press release with financial information and operating metrics for the quarter ended September 30, 2025, and discussed its outlook.

Which items of the 8-K apply to RVPH’s update?

Items 2.02 (Results of Operations and Financial Condition) and 7.01 (Regulation FD Disclosure).

Is the information considered filed with the SEC?

No. The information under Items 2.02 and 7.01 is being furnished and is not deemed “filed” for Section 18 liability.

What period does the update cover for RVPH?

The fiscal quarter ended September 30, 2025.

Where can I find the detailed financial press release?

It is included as Exhibit 99.1 to the 8-K.

What are RVPH’s listed securities and symbols?

Common Stock: RVPH; Warrants to purchase one share of Common Stock: RVPHW on Nasdaq Capital Market.